$324 Million is the total value of Tamarack Advisers, LP's 37 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCRX | Sell | PACIRA BIOSCIENCES INCequity | $39,379,000 | +7.2% | 655,000 | -6.4% | 12.14% | +18.7% |
| MDT | Buy | MEDTRONIC PLCequity | $25,980,000 | +88.9% | 250,000 | +66.7% | 8.01% | +109.1% |
| HOLX | Sell | HOLOGIC INCequity | $19,941,000 | +7.6% | 300,000 | -7.7% | 6.15% | +19.2% |
| PRGO | Sell | PERRIGO CO PLCequity | $19,741,000 | -24.8% | 430,000 | -9.5% | 6.08% | -16.8% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INCequity | $18,000,000 | +43.6% | 7,500,000 | +9.5% | 5.55% | +58.9% |
| UTHR | Sell | UNITED THERAPEUTICS CORPequity | $16,160,000 | -23.7% | 160,000 | -8.6% | 4.98% | -15.5% |
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $15,466,000 | +42.8% | 1,900,000 | +18.8% | 4.77% | +58.0% |
| LH | Buy | LABORATORY CRP OF AMER HLDGSequity | $15,062,000 | +64.9% | 80,000 | +45.5% | 4.64% | +82.5% |
| ATRC | Buy | ATRICURE INCequity | $13,965,000 | +38.1% | 350,000 | +55.6% | 4.30% | +52.8% |
| LNTH | LANTHEUS HOLDINGS INCequity | $12,037,000 | -11.4% | 950,000 | 0.0% | 3.71% | -1.9% | |
| NUAN | Sell | NUANCE COMMUNICATIONS INCequity | $11,617,000 | -20.2% | 350,000 | -39.1% | 3.58% | -11.6% |
| DGX | Sell | QUEST DIAGNOSTICS INCequity | $11,449,000 | -63.5% | 100,000 | -63.6% | 3.53% | -59.6% |
| ICUI | Sell | ICU MEDICAL INCequity | $11,148,000 | -22.5% | 61,000 | -21.8% | 3.44% | -14.1% |
| PLXS | Buy | PLEXUS CORPequity | $10,241,000 | +119.9% | 145,000 | +119.7% | 3.16% | +143.3% |
| PHR | Sell | PHREESIA INCequity | $9,639,000 | -14.8% | 300,000 | -25.0% | 2.97% | -5.7% |
| RDNT | Sell | RADNET INCequity | $9,594,000 | -13.6% | 625,000 | -10.7% | 2.96% | -4.4% |
| BIO | Sell | BIO-RAD LABORATORIES-Aequity | $7,732,000 | -42.9% | 15,000 | -50.0% | 2.38% | -36.8% |
| OPTN | Buy | OPTINOSE INCequity | $7,215,000 | -36.4% | 1,850,000 | +21.3% | 2.22% | -29.6% |
| STRM | STREAMLINE HEALTH SOLUTIONSequity | $6,717,000 | +17.3% | 4,305,882 | 0.0% | 2.07% | +29.9% | |
| AHCO | New | ADAPTHEALTH CORPequity | $6,652,000 | – | 305,000 | +100.0% | 2.05% | – |
| SIBN | Buy | SI-BONE INCequity | $5,811,000 | +246.5% | 245,000 | +132.9% | 1.79% | +283.5% |
| TPB | New | TURNING POINT BRANDS INCequity | $5,720,000 | – | 205,000 | +100.0% | 1.76% | – |
| ISEE | Sell | IVERIC BIO INCequity | $5,076,000 | -0.5% | 900,000 | -10.0% | 1.56% | +10.1% |
| EW | New | EDWARDS LIFESCIENCES CORPequity | $3,991,000 | – | 50,000 | +100.0% | 1.23% | – |
| MSON | Sell | MISONIX INCequity | $3,519,000 | -19.5% | 300,000 | -6.8% | 1.08% | -10.8% |
| PDCO | New | PATTERSON COS INCequity | $2,411,000 | – | 100,000 | +100.0% | 0.74% | – |
| New | GLD US 09/17/21 C200call | $2,363,000 | – | 3,000 | +100.0% | 0.73% | – | |
| QDEL | New | QUIDEL CORPequity | $2,194,000 | – | 10,000 | +100.0% | 0.68% | – |
| ALGN | New | ALIGN TECHNOLOGY INCequity | $1,637,000 | – | 5,000 | +100.0% | 0.50% | – |
| New | IWM US 11/20/20 P150put | $1,510,000 | – | 2,000 | +100.0% | 0.46% | – | |
| New | IBB US 10/16/20 P140put | $755,000 | – | 2,000 | +100.0% | 0.23% | – | |
| MYL | Sell | MYLAN NVequity | $742,000 | -88.5% | 50,000 | -87.5% | 0.23% | -87.2% |
| New | NUAN US 12/18/20 C35call | $630,000 | – | 3,000 | +100.0% | 0.19% | – | |
| New | MDT US 10/16/20 C105call | $334,000 | – | 2,000 | +100.0% | 0.10% | – | |
| New | TPB US 10/16/20 C30call | $52,000 | – | 1,000 | +100.0% | 0.02% | – | |
| Exit | XBI US 07/17/20 P105put | $0 | – | -2,000 | -100.0% | -0.08% | – | |
| Exit | SPY US 07/17/20 P290put | $0 | – | -4,000 | -100.0% | -0.25% | – | |
| Exit | TEVA US 09/18/20 C10call | $0 | – | -6,500 | -100.0% | -0.45% | – | |
| NTRA | Exit | NATERA INCequity | $0 | – | -60,000 | -100.0% | -0.83% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL-SP ADRdepository receipt | $0 | – | -250,000 | -100.0% | -0.86% | – |
| AMRS | Exit | AMYRIS INCequity | $0 | – | -1,333,333 | -100.0% | -1.58% | – |
| ABT | Exit | ABBOTT LABORATORIESequity | $0 | – | -75,000 | -100.0% | -1.91% | – |
| Exit | GLD US 01/15/21 C150call | $0 | – | -4,000 | -100.0% | -2.28% | – | |
| UNH | Exit | UNITEDHEALTH GROUP INCequity | $0 | – | -35,000 | -100.0% | -2.87% | – |
| GWPH | Exit | GW PHARMACEUTICALS -ADRdepository receipt | $0 | – | -90,000 | -100.0% | -3.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.